Technical Analysis for SYBX - Synlogic, Inc.

Grade Last Price % Change Price Change
F 1.46 1.39% 0.02
SYBX closed up 1.39 percent on Friday, November 1, 2024, on 1.66 times normal volume. It ran into resistance at its 50 day moving average.
Earnings due: Nov 7
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Wide Range Bar Range Expansion 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Gapped Up Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
50 DMA Resistance Bearish 1.39%
Shooting Star Candlestick Bearish 1.39%
Lizard Bearish Bearish Day Trade Setup 1.39%

   Recent Intraday Alerts

Alert Time
50 DMA Support about 21 hours ago
50 DMA Resistance about 21 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
Upper Bollinger Band Resistance about 22 hours ago
Gapped Up (Full) about 22 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Synlogic, Inc. Description

Synlogic, Inc., formerly Mirna Therapeutics, Inc., is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). It is also focused on Synthetic Biotic medicines to address other conditions, including inflammatory bowel disease , cancer and metabolic conditions, such as diabetes and obesity. The Company’s synthetic biotic medicines leverages the tools and principles of synthetic biology to genetically reengineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The Company’s pipeline includes synthetic biotic medicines for the treatment of inborn errors of metabolism (IEM). It is developing SYNB1020 for the treatment of UCD and HE. It is developing SYNB1618 for the treatment of PKU.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Disease Diabetes Obesity Inflammatory Bowel Disease Metabolism Genetic Diseases Synthetic Biology Inborn Errors Of Metabolism Rare Genetic Disease Rare Genetic Diseases Newborn Screening Intellectual Disability Phenylketonuria Pku Urea Cycle

Is SYBX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.1181
52 Week Low 1.22
Average Volume 9,097
200-Day Moving Average 1.76
50-Day Moving Average 1.47
20-Day Moving Average 1.44
10-Day Moving Average 1.44
Average True Range 0.08
RSI (14) 51.22
ADX 22.76
+DI 28.85
-DI 7.05
Chandelier Exit (Long, 3 ATRs) 1.41
Chandelier Exit (Short, 3 ATRs) 1.63
Upper Bollinger Bands 1.51
Lower Bollinger Band 1.37
Percent B (%b) 0.66
BandWidth 9.42
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram 0.0059
Fundamentals Value
Market Cap 13.42 Million
Num Shares 9.19 Million
EPS -12.68
Price-to-Earnings (P/E) Ratio -0.12
Price-to-Sales 43.51
Price-to-Book 0.37
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.76
Resistance 3 (R3) 1.79 1.72 1.71
Resistance 2 (R2) 1.72 1.64 1.71 1.69
Resistance 1 (R1) 1.59 1.60 1.56 1.56 1.68
Pivot Point 1.52 1.52 1.50 1.51 1.52
Support 1 (S1) 1.39 1.44 1.36 1.36 1.24
Support 2 (S2) 1.32 1.40 1.31 1.23
Support 3 (S3) 1.19 1.32 1.21
Support 4 (S4) 1.16